Tarlatamab-Durvalumab Maintenance Extends Survival in Small-Cell Lung Cancer

A phase 3 randomized trial (DeLLphi-305) compared tarlatamab-durvalumab versus durvalumab alone as first-line maintenance therapy in extensive-stage small-cell lung cancer patients without progression after initial chemoimmunotherapy. The trial reported median overall survival of 21.1 months with tarlatamab-durvalumab versus 12.7 months with durvalumab alone, and median progression-free survival of 7.4 versus 1.9 months, respectively. The trial also reported grade 3 or higher adverse events in 46.8% versus 40.6% of patients, with cytokine release syndrome, mainly grade 1 or 2, occurring in nearly half of those receiving tarlatamab-durvalumab.

Most relevant for: Patients with extensive-stage small-cell lung cancer who have not progressed after initial chemoimmunotherapy and are candidates for maintenance therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.